Palbociclib Tablet Suppliers & Bulk Manufacturers

Available Forms: Oral Tablets

Available Strengths: 75 mg, 100mg, 125 mg

Reference Brands: Ibrance® (US & EU)

Category: Oncology Cancer Care

Palbociclib Tablets (brand name Ibrance®) are used to treat HR+ HER2-negative breast cancer. As a CDK 4/6 inhibitor, it halts cancer cell division. Available in 125 mg, 100 mg, and 75 mg strengths, Palbociclib is used in combination with letrozole or fulvestrant for advanced or metastatic cases. Manufactured under GMP standards, it is a trusted oncology treatment for US and EU markets. Palbociclib Tablet is available in Oral Tablets and strengths such as 75 mg, 100mg, 125 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Palbociclib Tablet is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Palbociclib Tablet can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Palbociclib Tablets are a CDK 4/6 inhibitor used for the treatment of hormone receptor-positive (HR+), HER2-negative breast cancer. It works by blocking the proteins responsible for cancer cell division, halting cell cycle progression. Marketed under the brand name Ibrance®, Palbociclib is typically used in combination with letrozole or fulvestrant for the treatment of advanced or metastatic breast cancer. Available in 125 mg, 100 mg, and 75 mg tablet strengths, Palbociclib is manufactured in GMP-compliant facilities, making it a reliable and effective solution for oncology treatment in both US and EU markets.